References
- Marijon E, Mirabel M, Celermajer DS, et al. Rheumatic heart disease. Lancet. 2012;379:953–964.
- Murni IK, Musa NL. The need for specialized pediatric cardiac critical care training program in limited resource settings. Front Pediatr. 2018;6:1–5.
- Musa NL, Hjortdal V, Zheleva B, et al. The global burden of paediatric heart disease. Cardiol Young. 2017;27:6–11.
- Zühlke LJ, Engel ME, Watkins D, et al. Incidence, prevalence and outcome of rheumatic heart disease in South Africa: a systematic review of contemporary studies. Int J Cardiol. 2015;199:375–383.
- Zuhlke L, Karthikeyan G, Engel ME, et al. Clinical outcomes in 3343 children and adults with rheumatic heart disease from 14 low- and middle-income countries: two-year follow-up of the Global Rheumatic Heart Disease Registry (the REMEDY Study). Circulation. 2016;134:1456–1466.
- Cannon J, Roberts K, Milne C, et al. Rheumatic heart disease severity, progression and outcomes: a multi‐state model. J Am Hear Assoc 2017; 6:e003498.
- Meira ZMA, Goulart EMA, Colosimo EA, et al. Long term follow up of rheumatic fever and predictors of severe rheumatic valvar disease in Brazilian children and adolescents. Heart. 2005;91:1019–1022.
- Engelman D, Wheaton GR, Mataika RL, et al. Screening-detected rheumatic heart disease can progress to severe disease. Heart Asia. 2016;8:67–73.
- Lilyasari O, Prakoso R, Kurniawati Y, et al. Clinical profile and management of rheumatic heart disease in children and young adults at a tertiary cardiac center in Indonesia. Front Surg. 2020;7:1–9.
- Reményi B, Wilson N, Steer A, et al. World Heart Federation criteria for echocardiographic diagnosis of rheumatic heart disease – an evidence-based guideline. Nat Rev Cardiol. 2012;9:297–309.
- Zoghbi W. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr. 2003;16:777–802.
- Shrestha NR, Pilgrim T, Karki P, et al. Rheumatic heart disease revisited: patterns of valvular involvement from a consecutive cohort in eastern Nepal. J Cardiovasc Med (Hagerstown). 2012;13:755–759.
- de Onis M, Onyango AW, Borghi E, et al. Development of a WHO growth reference for school-aged children and adolescents. Bull WHO. 2007;85:660–667.
- Freeman RV, Otto CM. Spectrum of calcific aortic valve disease: pathogenesis, disease progression, and treatment strategies. Circulation. 2005;111:3316–3326.
- Attar A, Marzban P, Moaref A, et al. The association of plasma high-sensitivity C-reactive protein level with rheumatic heart disease: the possible role of inflammation. Indian Heart J. 2018;70:346–349.
- Gölbasi Z, Uçar O, Keles T, et al. Increased levels of high sensitive C-reactive protein in patients with chronic rheumatic valve disease: evidence of ongoing inflammation. Eur J Heart Fail. 2002;4:593–595.
- Thakur JS, Negi PC, Ahluwalia SK, et al. Epidemiological survey of rheumatic heart disease among school children in the Shimla Hills of northern India: prevalence and risk factors. J Epidemiol Community Health. 1996;50:62–67.
- Manyemba J, Mayosi BM. Intramuscular penicillin is more effective than oral penicillin in secondary prevention of rheumatic fever – a systematic review. South Afr Med J. 2003;93:212–218.
- Manyemba J, Mayosi BM, Manyemba J, et al. Penicillin for secondary prevention of rheumatic fever (review). Cochrane Database Syst Rev. 2009;4. CD002227.
- Edwards BS, Edwards JE. Congestive heart failure in rheumatic carditis: valvular or myocardial origin? J Am Coll Cardiol. 1993;22:830–831.